BidaskClub upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a report issued on Wednesday morning.
Separately, Zacks Investment Research upgraded ICU Medical from a hold rating to a buy rating and set a $232.00 price target on the stock in a report on Thursday, November 16th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $266.00.
Shares of ICU Medical (ICUI) traded up $5.45 during trading hours on Wednesday, reaching $261.85. The company’s stock had a trading volume of 72,438 shares, compared to its average volume of 88,478. The company has a market capitalization of $5,271.30, a price-to-earnings ratio of 78.63, a P/E/G ratio of 2.76 and a beta of 0.42. The company has a current ratio of 4.65, a quick ratio of 3.01 and a debt-to-equity ratio of 0.07. ICU Medical has a 1-year low of $144.25 and a 1-year high of $263.05.
In other news, CFO Scott E. Lamb sold 23,624 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $220.00, for a total value of $5,197,280.00. Following the completion of the sale, the chief financial officer now directly owns 29,723 shares of the company’s stock, valued at $6,539,060. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert S. Swinney sold 724 shares of the stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $235.00, for a total value of $170,140.00. Following the completion of the sale, the director now directly owns 14,830 shares of the company’s stock, valued at $3,485,050. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.
Several institutional investors have recently modified their holdings of ICUI. Exane Derivatives purchased a new stake in shares of ICU Medical in the fourth quarter worth approximately $100,000. Israel Discount Bank of New York raised its stake in shares of ICU Medical by 74.8% in the fourth quarter. Israel Discount Bank of New York now owns 853 shares of the medical instruments supplier’s stock worth $184,000 after purchasing an additional 365 shares during the last quarter. Eagle Boston Investment Management Inc. purchased a new stake in shares of ICU Medical in the third quarter worth approximately $200,000. First Republic Investment Management Inc. purchased a new stake in shares of ICU Medical in the fourth quarter worth approximately $200,000. Finally, Raymond James Trust N.A. purchased a new stake in shares of ICU Medical in the fourth quarter worth approximately $204,000. 76.24% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3255811/icu-medical-icui-stock-rating-upgraded-by-bidaskclub.html.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.